Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone

International Journal of Cancer

Volumn 83, Issue 2, 1999, Pages 263-269

  Magnetto, Sandrine ^a   Boissier, Sandrine ^a   Delmas, Pierre D ^b   Clezardin, Philippe ^a  

^a INSERM   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; IBANDRONIC ACID; PACLITAXEL;

ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER INHIBITION; CANCER INVASION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION; DIPHOSPHONATES; DRUG SYNERGISM; HUMANS; NEOPLASM INVASIVENESS; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0032881209     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T     Document Type: Article

References (22)

1. BAE, S.N., ARAND, G., AZZAM, H., PAVASANT, P., TORRI, J., FRANDSEN, T.L. and THOMPSON, E.W., Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays. Breast Cancer Res. Treat., 24, 241-255 (1993).
2. BASELGA, J., NORTON, L., ALBANELL, J., KIM, V.M. and MENDELSOHN, J., Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58, 2825-2831 (1998).
3. BELOTTI, D., RIEPPI, M., NICOLETTI, M.I., CASAZZA, A.M., FOJO, T., TARABOLETTI, G. and GIAVAZZI, R., Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin. Cancer Res., 2, 1725-1730 (1996).
4. BOISSIER, S., MAGNETTO, S., FRAPPART, L., CUZIN, B., EBETINO, F.H., DELMAS, P.D. and CLEZARDIN, P., Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res., 57, 3890-3894 (1997).
5. CORTES, J.E. and PAZDUR, R., Docetaxel. J. clin. Oncol., 13, 2643-2655 (1995).
6. DIEL, I.J., SOLOMAYER, E.F., COSTA, S.D., GOLLAN, C., GOERNER, R., WALLWIERNER, D., KAUFFMANN, M. and BASTERT, G., Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med., 339, 357-363 (1998).
7. HALL, T.J., JEKER, H. and SCHAUEBLIN, M., Taxol inhibits osteoclastic bone resorption. Calcif. Tissue Int., 57, 463-465 (1995).
8. HORTOBAGYI, G.N., THERIAULT, R.L., PORTER, L., BLAYNEY, D., LIPTON, A., SINOFF, C., WHEELER, H., SIMEONE, J.F., SEAMAN, J. and KNIGHT, R.D., Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med., 335, 1785-1791 (1996).
9. KODALI, S., BURKLEY, M., NAG, K., TAYLOR, R.C. and MOUDGIL, V.K., Taxol and cisplatin inhibit proliferation of T47D human breast cancer cells. Biochem. biophys. Res. Comm., 202, 1413-1419 (1994).
10. LIPTON, A., Bisphosphonates and breast carcinoma. Cancer, 80, 1668-1673 (1997).
11. MAGNETTO, S., BRUNO-BOSSIO, G., VOLAND, C., LECERF, J., LAWLER, J., DELMAS, P., SILVERSTEIN, R. and CLEZARDIN, P., CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1. Cell Biochem. Funct., 16, 211-221 (1998).
12. MOASSER, M.M., SEPP-LORENZINO, L., KOHL, N.E., OLIFF, A., BALOG, A., SU, D.S., DANISHEFSKY, S.J. and ROSEN, N., Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. nat. Acad. Sci. (Wash.), 95, 1369-1374 (1998).
13. MUNDY, G.R., Mechanisms of bone metastasis. Cancer, 80, 1546-1556 (1997).
14. RINGEL, I. and HORWITZ, S.B., Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. nat. Cancer Inst., 83, 288-291 (1991).
15. SASAKI, A., BOYCE, B.F., STORY, B., WRIGHT, K.R., CHAPMAN, M., BOYCE, R., MUNDY, G.R. and YONEDA, T., Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res., 55, 3551-3557 (1995).
16. SAUNDERS, D.E., LAWRENCE, W.D., CHRISTENSEN, C., WAPPLER, N.L., RUAN, H. and DEPPE, G., Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int. J. Cancer, 70, 214-220 (1997).
17. SHIPMAN, C.M., ROGERS, M.J., APPERLEY, J.F., RUSSEL, R.G. and CROUCHER, P.I., Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Brit. J. Haematol., 98, 665-672 (1997).
18. STEARNS, M.E. and WANG, M., Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res., 52, 3776-3781 (1992).
19. STEARNS, M.E. and WANG, M., Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis, 16, 116-131 (1996).
20. TERONEN, O., KONTTINEN, Y.T., LINDQVIST, C., SALO, T., INGMAN, T., LAUHIO, A., DING, Y., SANTAVIRTA, S., VALLEALA, H. and SORSA, T., Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif. Tissue Int., 61, 59-61 (1997).
21. VAN DER PLUIJM, G., VLOEDGRAVEN, H., VAN BEEK, E., VAN DER WEE-PALS, L., LOWIK, C. and PAPAPOULOS, S., Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. clin. Invest., 98, 698-705 (1996).
22. YONEDA, T., SASAKI, A., DUNSTAN, C., WILLIAMS, P.J., BAUSS, F., DE CLERCK, Y.A., and MUNDY, G.R., Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest., 99, 2509-2517 (1997).